NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
85.97
+1.07 (+1.26%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close84.90
Open84.69
Bid0.00 x 2200
Ask0.00 x 900
Day's Range84.69 - 85.98
52 Week Range72.30 - 94.19
Volume3,142,491
Avg. Volume1,759,518
Market Cap196.096B
Beta0.91
PE Ratio (TTM)14.61
EPS (TTM)5.88
Earnings DateN/A
Forward Dividend & Yield2.98 (3.49%)
Ex-Dividend Date2018-03-06
1y Target Est98.50
Trade prices are not sourced from all markets
  • TheStreet.com10 hours ago

    Novartis Is Ready to Rally From a Large Base Pattern

    In this updated daily bar chart of NVS, below, we can see a strong rally from late June. In early September the 50-day line crossed above the 200-day line for what is commonly called a golden cross. The On-Balance-Volume (OBV) line turned up in July signaling more aggressive buying but has been stalled the past six weeks.

  • Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
    Zacks13 hours ago

    Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

    Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

  • Cannabis Company Tilray's (TLRY) Shares Up 856% Since July
    Zacks15 hours ago

    Cannabis Company Tilray's (TLRY) Shares Up 856% Since July

    Tilray (TLRY) inks an import deal with the U.S. Drug Enforcement Administration for a trial on neurological movement disorder.

  • Benzingayesterday

    Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation

    In the next few years, Ulz said he anticipates "meaningful upside" stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. The drug has broad utility and a differentiated safety profile, Ulz said. A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.

  • The Wall Street Journalyesterday

    [$$] Novartis' CAR-T Drug Hits First Setback in Europe

    AG’s (NOVN.EB) immunotherapy Kymriah is too expensive to be recommended for use in adults with B-cell lymphoma that have relapsed or haven’t responded to first-line treatment, a U.K. regulator said Wednesday, despite the Swiss pharma giant offering a discount on its hefty list price--the first major setback for the company’s drug in Europe. The National Institute for Health and Care Excellence earlier this month recommended the therapy for use in pediatric patients with a different kind of blood cancer. In a statement, NICE recognized that Kymriah had significant clinical benefits, with response rates of about 40% in two studies, and overall survival rates of about one to two years.

  • UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
    Reuters2 days ago

    UK rejects adult Novartis CAR-T therapy, after 'yes' in kids

    Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people. The National Institute for Health and Care Excellence (NICE) said Kymriah was not cost-effective for adult lymphoma. The decision on Kymriah in adults is in line with the rejection of a rival CAR-T treatment for adult lymphoma from Gilead Sciences.

  • Reuters2 days ago

    UK rejects adult Novartis CAR-T therapy, after 'yes' in kids

    Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people. The National Institute for Health and Care Excellence (NICE) said Kymriah was not cost-effective for adult lymphoma. The decision on Kymriah in adults is in line with the rejection of a rival CAR-T treatment for adult lymphoma from Gilead Sciences.

  • Novartis Cancer Therapy Kymriah Hits First Hurdle in Europe
    Bloomberg2 days ago

    Novartis Cancer Therapy Kymriah Hits First Hurdle in Europe

    Novartis AG’s cancer drug Kymriah faced its first setback in Europe as U.K. health authorities made an initial recommendation against paying for the breakthrough therapy to treat a form of lymphoma in adults. Although the one-time treatment has demonstrated significant benefits, and Novartis had offered an undisclosed discount on the list price of 282,000 pounds ($372,000), Kymriah isn’t adequately cost-effective for routine funding, the National Institute for Health and Care Excellence said in a statement Wednesday. Novartis said it’s disappointed with the preliminary decision, and that it may be difficult to assess the value of new treatments like Kymriah that are aimed at curing lethal diseases.

  • Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
    Market Realist3 days ago

    Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval

    On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.

  • Competition Dynamics for Ajovy—Teva’s Migraine Drug
    Market Realist3 days ago

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.

  • Novartis links bonuses to ethics in bid to rebuild reputation
    Reuters3 days ago

    Novartis links bonuses to ethics in bid to rebuild reputation

    Swiss drugmaker Novartis (NOVN.S) has revealed its employees only get a bonus if they meet or exceed expectations for ethical behavior as it seeks to address past shortcomings that have damaged its reputation. Chief Executive Vas Narasimhan has made strengthening the Swiss drugmaker's ethics culture a priority after costly bribery scandals or legal settlements in South Korea, China and the United States. Receiving a 2, which Novartis said denotes meeting expectations, or a 3, for "role model" behavior, would make them eligible for a bonus of up to 35 percent of their total compensation.

  • Reuters3 days ago

    Novartis links bonuses to ethics in bid to rebuild reputation

    Swiss drugmaker Novartis (NOVN.S) has revealed its employees only get a bonus if they meet or exceed expectations for ethical behaviour as it seeks to address past shortcomings that have damaged its reputation. Chief Executive Vas Narasimhan has made strengthening the Swiss drugmaker's ethics culture a priority after costly bribery scandals or legal settlements in South Korea, China and the United States. Receiving a 2, which Novartis said denotes meeting expectations, or a 3, for "role model" behaviour, would make them eligible for a bonus of up to 35 percent of their total compensation.

  • TheStreet.com4 days ago

    Teva Shares Pop as FDA Approves Its Migraine Drug

    American depository receipts jumped in morning trading on Monday, Sept. 17, following the news late Friday that the company had clinched the U.S. Food and Drug Administration's nod for its migraine drug. It is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the agency to prevent migraines, after Amgen Inc. CGRP is thought to play a key role in causing migraine headaches.

  • Lenvima Could Significantly Boost Merck’s Revenue Growth
    Market Realist4 days ago

    Lenvima Could Significantly Boost Merck’s Revenue Growth

    In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.

  • How Is Merck’s Keytruda Positioned in September?
    Market Realist4 days ago

    How Is Merck’s Keytruda Positioned in September?

    Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.

  • How Spark Therapeutics Is Positioned in 2018
    Market Realist6 days ago

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.

  • Benzinga8 days ago

    The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...

  • Zacks9 days ago

    KemPharm Posts Positive Top-Line Results on KP415 Prodrug

    KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.

  • Alcon to Set Up Future Global Headquarters in Geneva
    Market Realist9 days ago

    Alcon to Set Up Future Global Headquarters in Geneva

    Alcon, the eyecare business of Novartis (NVS), includes surgical products and vision care products. It announced today that it will locate its future headquarters in Geneva after spinning off from Novartis.

  • Alcon shifting global HQ from Fort Worth to Geneva
    American City Business Journals9 days ago

    Alcon shifting global HQ from Fort Worth to Geneva

    Alcon, one of Fort Worth's biggest companies, is shifting its global headquarters to Geneva after the completion of the eye product firm’s spinoff from parent company Novartis, the companies announced today.

  • Reuters10 days ago

    Alcon picks Geneva over Texas for new HQ

    The headquarters of Alcon, the eyecare unit of Novartis which will be spun off to shareholders in 2019, will move from the division's longtime corporate home in the Dallas suburbs to the Swiss city of Geneva, Novartis said in a statement on Tuesday. Alcon's current global divisional headquarters in Fort Worth, Texas, will remain a major site but the company plans to employ up to 700 people in tax-friendly Switzerland after the spin-off, which aims to create a separate publicly listed company.

  • The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

  • Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
    Zacks14 days ago

    Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

    Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

  • Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA
    Zacks14 days ago

    Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA

    The FDA extends the review period for Roche's sBLA for Tecentriq in combination with Avastin for the initial treatment of NSCLC by three months.

  • The Wall Street Journal14 days ago

    [$$] Novartis to Sell Parts of Sandoz for $1 Billion

    Novartis AG on Thursday said it would sell parts of its Sandoz generic-drugs business in the U.S. in a deal worth up to $1 billion, the latest move by its new chief executive to refocus the Swiss pharmaceuticals giant. The Basel-based company said it would sell assets including Sandoz’s U.S. dermatology business and generic oral solids portfolio to India’s Aurobindo Pharma Ltd. for $900 million in cash and up to $100 million based on performance. Novartis said the sale was part of its broader strategy to pivot Sandoz toward higher-growth areas, such as more complex generics, value-added medicines and biosimilars—near-replicas of biologic drugs, which are made using living cells.